Definition

A preparation of autologous T lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) that targets an as of yet unidentified tumor-associated antigen (TAA), with potential immunomodulatory and antineoplastic activities. Upon administration of autologous CAR T cells RD14-01, the T cells target, bind to and induce selective cytotoxicity in tumor cells expressing the TAA.